Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $25.47. The company's market cap stands at 145.19B, with a P/E ratio of 19.65 and a dividend yield of 6.7%.
On 2026-06-02, Pfizer(PFE) stock moved within a range of $25.27 to $25.71. With shares now at $25.47, the stock is trading +0.8% above its intraday low and -0.9% below the session's peak.
Trading activity shows a volume of 14.59M, compared to an average daily volume of 33.08M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.06.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.06.
PFE News
Why Pfizer’s Current Price May Be Too Cheap to Ignore By Vandita Jadeja Published Jun 2, 10:03AM EDT Quick Read Pfizer (PFE) trades at $26.18 with a 24/7 Wall...
Pfizer reported new seven-year data from the Phase 3 CROWN trial at ASCO 2026, highlighting LORBRENA for untreated ALK-positive advanced non small cell lung can...
In trading on Monday, shares of Pfizer Inc (Symbol: PFE) crossed below their 200 day moving average of $25.83, changing hands as low as $25.48 per share. Pfizer...
Analyst ratings
55%
of 29 ratingsMore PFE News
Key Points AbbVie leverages a strong pipeline in immunology and oncology to drive nearly $61.2 billion in annual revenue. Pfizer maintains a diverse portfolio...
Key Points Pfizer could flourish under a Warsh-led Fed for several reasons. However, the drugmaker won't be a slam-dunk winner, in part because of its debt an...
UBS analyst Michael Yee has maintained their neutral stance on PFE stock, giving a Hold rating on May 28. Unlock trusted, data-backed investing tools with TipR...
Pfizer (PFE) announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 Breakwater trial, evaluating Bra...
Key Points Pfizer is dealing with what are really just normal headwinds for a drug company. Although the near term is likely to be challenging, a material sto...
Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Memorial Day Sale – Claim 70% Off TipRanks Unlock tr...
Pfizer (NYSE:PFE) has agreed a global oncology partnership with Innovent Biologics valued at up to $10.5b. The alliance gives Pfizer access to 12 early stage c...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.